Clinical trials: Pituitary Disease
Hypopituitarism
Effects of Corticotropin Releasing Hormone (CRH) on the Sleep in Patients With Hypopituitarism
In contrast to healthy subjects, patients with hypopituitarism do not exhibit endocrine responses when hormones are injected. This is at least true for those with a complete insufficiency of the anterior pituitary.
- Trial name
- NCT00666068
- Testing
- corticotropin releasing hormone (CRH)
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Max-Planck-Institute of Psychiatry
Adult Growth Hormone Deficiency
Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety
ALTU-238 is a long acting crystalline formulation of recombinant human growth hormone (rhGH) that is being developed for the treatment of growth hormone deficiency in adults and children.
- Trial name
- NCT00297713
- Testing
- ALTU-238
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Altus Pharmaceuticals
Growth Hormone Deficiency, Short Stature
Biological Age in Children With GH Deficiency Undergoing Hormone Replacement Therapy
The primary objective of the study is to evaluate the epigenetic age in children with GH deficiency, before and after 6 months of treatment with growth hormone replacement therapy.
- Trial name
- ETABIOGHD (NCT06294860)
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Istituto Auxologico Italiano
Hyperprolactinemia
A Study on Bioequivalence of Cabergoline Tablets in Human Body
The purpose of this study is to evaluate the bioequivalence of the test formulation and reference formulation of cabergoline tablets in healthy Chinese subjects under fasting and postprandial conditions.
- Trial name
- NCT07008417
- Testing
- Cabergoline tablets test formulation, Cabergoline tablets reference formulation
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Growth Hormone Disorder, Pituitary Dwarfism
Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children
This trial is conducted in the United States of America (USA). This is a 12 month study to determine if Norditropin is safe and effective in children with IGF deficiency.
- Trial name
- NCT00102817
- Testing
- somatropin
- Where
- 27 sites in United States
- Volunteers
- 149 people
- Sponsor
- Novo Nordisk A/S
Infertility
Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) Response to Low Dose Clomiphene Citrate in Normally Menstruating Fertile Women
The goal of the study is to quantitatively evaluate pituitary hormone response, follicle stimulating hormone (FSH) and luteinizing hormone (LH), to low doses of clomiphene citrate in normally fertile women.
- Trial name
- NCT01340521
- Testing
- Clomiphene Citrate
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Pituitary Tumor, Optic Chiasm Disorder
Visual Outcome After Transsphenoidal Surgery for Pituitary Macroadenoma
Endoscopic endonasal transsphenoidal surgery is a procedure for the treatment of pituitary macroadenomas that cause visual impairment through optic chiasm compression.
- Trial name
- RetroADEN (NCT03363126)
- Testing
- Endonasal transsphenoidal pituitary tumor removal
- Volunteers
- 88 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Pituitary Adenoma, Cushing Disease
Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors
This pilot and feasibility study aims to combine recent advances in ultrasound imaging, specifically an endonasal transducer array and contrast enhanced ultrasound, to offer an intraoperative image-guided solution for…
- Trial name
- NCT07335315
- Testing
- Contrast enhanced pituitary magnetic resonance imaging (MRI), Contrast enhanced ultrasound, Non-Contrast Ultrasound
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Mayo Clinic
Acromegaly
Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations in Acromegaly
Acromegaly is a rare disease caused by growth hormone (GH) secreting pituitary adenoma in more than 95% of cases. Acromegaly can be seen sporadically or may be associated with a variety of genetic syndromes such as Multiple…
- Trial name
- AIP (NCT01902420)
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- TC Erciyes University
Hyponatremia, SIADH
Hyponatraemia and Mortality in Schizophrenic and Bipolar Patients: Protocol for a Bayesian Causal Inference Study
This study seeks to investigate if hyponatraemia be a direct contributor to death in schizophrenic and bipolar patients, and gauge the potential role of somatic comorbidity and psychotropic polypharmacy, with emphasis on…
- Trial name
- NCT04409626
- Testing
- Plasma sodium level (continuous variables)
- Volunteers
- 31,740 people
- Sponsor
- Zealand University Hospital
Hepatic Steatosis, Pituitary Gland Failure
Hepatic Steatosis and Pituitary Gland Failure, Evaluation by Nuclear Magnetic Resonance (NMR) Imaging
The investigator put forward the hypothesis that liver fat mass in patients with pituitary gland failure is greater than that in a control population.
- Trial name
- SHAH (NCT02814240)
- Testing
- NMR, Blood samples, fibroscan
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Major Depressive Disorder
Evaluation of the Potential Effects of SSR149415 on the Hypothalamic-pituitary-adrenal Axis in Outpatients With Major Depressive Disorder
Primary Objective: To evaluate the effects of two fixed doses of SSR149415 (250 mg bid and 100 mg bid) on hypothalamic-pituitary-adrenal axis function in patients with major depressive disorder.
- Trial name
- NAPA (NCT01606384)
- Testing
- VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Sanofi
Acromegaly, Neuroendocrine Tumours
Somatuline Predictive Factors in Acromegaly and NET
The aim of the study is to identify predictive factors for the response to Lanreotide treatment in Acromegaly as well as in Neuroendocrine Tumours.
- Trial name
- SOPRANo (NCT01840449)
- Testing
- Somatuline Autogel® 60, 90 or 120 mg
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 156 people
- Sponsor
- Ipsen
Traumatic Shock
AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock
Trauma patients, who are transfused with multiple blood products to treat shock due to blood loss, frequently develop inappropriately low vasopressin levels.
- Trial name
- AVERTShock (NCT01611935)
- Testing
- Vasopressin
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- University of Pennsylvania
Pituitary Adenomas
Genome-wide Association Study of Pituitary Tumors
Pituitary adenomas is a very common disease, but the cause and genetics hasn't been identified. The investigators are going to use genome-wide association study to identify genes that may be related to pituitary adenomas.
- Trial name
- NCT01442220
- Where
- China
- Volunteers
- 12,500 people, healthy volunteers welcome
- Sponsor
- Huashan Hospital
Acromegaly
ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly
The primary objective of this study is to evaluate the efficacy of 15-week treatment with ALXN2420 versus placebo for decreasing insulin-like growth factor IGF-1 levels, when administered in combination with somatostatin analog…
- Trial name
- ASTERIA (NCT07037420)
- Testing
- ALXN2420
- Where
- 6 sites in United States, Italy and 2 more
- Volunteers
- 8 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Acromegaly
A Study to Evaluate MAR002 for Acromegaly
Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in participants with acromegaly
- Trial name
- NCT07641179
- Testing
- MAR002
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Marea Therapeutics
Pituitary Adenoma
Application of Radiomics in the Diagnosis and Treatment Prediction of Pituitary Adenoma
The images of patients with Pituitary adenoma were collected and analyzed based on the methods of radiomics.
- Trial name
- RIPA (NCT06234553)
- Testing
- surgery of pituitary adenomas
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Beijing Tiantan Hospital
Obesity, Growth Hormone
Prevalence and Cardiovascular Effects of Growth Hormone Deficiency in Abdominal Obesity
Obesity is one of the leading causes of cardiovascular-related diseases, including diabetes and heart disease. Obesity, and more specifically abdominal obesity, may cause decreased growth hormone (GH) levels.
- Trial name
- NCT00562796
- Where
- United States
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Acromegaly
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
This study will evaluate the efficacy and safety of pasireotide LAR 40 and 60 mg versus octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly.
- Trial name
- PAOLA (NCT01137682)
- Testing
- Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg
- Where
- 60 sites in United States, Argentina and 16 more
- Volunteers
- 198 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.